Opinion

Video

Landon Trost, MD, on platelet-rich plasma for Peyronie disease

Key Takeaways

  • PRP is popular for Peyronie disease due to its availability and safety, using patients' own biological factors.
  • Limited data exist on PRP's efficacy for Peyronie disease, with studies showing no significant outcome differences.
SHOW MORE

In this video from the 2024 Sexual Medicine Society of North America Fall Scientific Meeting, Landon Trost, MD, discusses the use of platelet-rich plasma for treating Peyronie disease. Trost is the founder and director of the Male Fertility and Peyronie’s Clinic in Orem, Utah.

Transcription:

What is the current evidence base supporting PRP use for Peyronie disease, and in what patient populations might it be considered a viable option?

PRP has really increased in popularity because it's readily available. It's not dangerous. It's using people's own factors, and there's some in vitro evidence to suggest it may work. And then in other fields, like orthopedics, there are data showing that it does work in certain areas. It's increased in popularity for erectile dysfunction, and more recently, people have been looking at it for Peyronie's disease. The problem in Peyronie's right now is there's just a lack of data. And of the data that are out there, the data showed no difference in outcomes after the randomized phase with it. But, even with that, some people still administer it and recommend it. We're currently working on a position statement for the Sexual Medicine Society of North America that will release at the AUA here in May of 2025 that will give the society's position on that particular therapy.

This transcript was AI generated and edited by human editors for clarity.

Related Videos
Mohamad Baker Berjaoui, MD, answers a question during a Zoom video interview
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Justin Dubin, MD, answers a question during a video interview
Phillip M. Pierorazio, MD, answers a question during a video interview
Michael Jenson, PA-C, answers a question during a Zoom video interview
Related Content
© 2024 MJH Life Sciences

All rights reserved.